At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 59 enrolled
Drug / intervention
Imatinib mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)
In Brief
A Phase 3 clinical trial evaluating Imatinib mesylate and Placebo for Pulmonary Arterial Hypertension. Completed, enrolled 59 participants across 13 sites in 4 countries.
Detailed Summary
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesAustria, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedMay 2007
Primary CompletionJan 2014
TodayJul 2026
First PostedMay 23, 2007
Enrollment StartApr 1, 2006
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 19.1 years ago
Interventions
Imatinib mesylatedrug
Placebodrug